A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)
Phase 1
Recruiting
- Conditions
- Juvenile Idiopathic ArthritisTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Registration Number
- CTIS2023-506131-15-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 184
Inclusion Criteria
Participants must have completed a previous study of baricitinib for the treatment of JIA, Participants must have not developed an allergy to baricitinib
Exclusion Criteria
Participants must not have permanently stopped baricitinib in the prior study, Participants must have not developed an allergy to baricitinib
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method